

HR 2038

State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 2, 2019

Current Status: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

Latest Action: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. (May 15, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/2038>

Sponsor

Name: Rep. Meadows, Mark [R-NC-11]

Party: Republican • **State:** NC • **Chamber:** House

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Budd, Ted [R-NC-13]	R · NC		Apr 15, 2019
Rep. Lesko, Debbie [R-AZ-8]	R · AZ		Oct 17, 2019

Committee Activity

Committee	Chamber	Activity	Date
Judiciary Committee	House	Referred to	May 15, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 4796	Related bill	Oct 5, 2020: Read twice and referred to the Committee on Finance.
116 HR 8527	Related bill	Oct 2, 2020: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Education and Labor, the Judiciary, Oversight and Reform, House Administration, Rules, the Budget, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Summary (as of Apr 2, 2019)

State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019

This bill authorizes health insurance issuers to jointly negotiate the prices for prescription drugs with the manufacturers of such drugs.

Actions Timeline

- **May 15, 2019:** Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
- **Apr 2, 2019:** Introduced in House
- **Apr 2, 2019:** Referred to the House Committee on the Judiciary.